Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31647336 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29569815 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119468 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29362229 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29850382 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL13401519 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL25356641 | 1.00 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL4600663 | 0.97 | KMT2A (0.56) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL4882849 | 0.97 | KMT2A (0.56) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401108 | 0.97 | KMT2A (0.56) | KMT2AMDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920804-B | Cetrorelix synthesis process capable of being directly used for pilot scale amplification | 厦门胜泽泰医药科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-117890507-A | Liquid chromatography detection method for protecting amino acid impurities | 江苏诺泰澳赛诺生物制药股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-116217672-A | Pure gonadotropin releasing hormone antagonist cetrorelix | 海南中和药业股份有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-115541733-A | Method for measuring protected amino acid enantiomer by reverse phase chromatography | 南京锐志生物医药有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-114920804-A | Sitrorelix synthesis process capable of being directly used for pilot amplification | 厦门胜泽泰医药科技有限公司 | 2022-08-19 | — | — | CN | claimed |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | Technische Universität München (DE) | 2026-03-17 | — | — | US | disclosed |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| EP-4631959-A2 | NOVEL MINIGASTRIN-DERIVED CHOLECYSTOKININ 2 RECEPTOR BINDING MOLECULES FOR IMAGING AND TARGETED RADIOTHERAPY | Technische Universität München, in Vertretung des Freistaates Bayern (DE) | 2025-10-15 | — | — | EP | disclosed |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2025-10-09 | — | — | US | disclosed |
| EP-4590347-A1 | NOVEL MINIGASTRIN-DERIVED CHOLECYSTOKININ 2 RECEPTOR BINDING MOLECULES FOR IMAGING AND TARGETED RADIOTHERAPY | Technische Universität München (DE) | 2025-07-30 | — | — | EP | disclosed |
| CN-119907695-A | Novel small gastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy | 慕尼黑工业大学 | 2025-04-29 | — | — | CN | disclosed |
| EP-4291250-B1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2025-01-15 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114920804-A | Sitrorelix synthesis process capable of being directly used for pilot amplification | 厦门胜泽泰医药科技有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022171901-A1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | Technische Universität München (DE) | 2022-08-18 | — | — | WO | disclosed |
| CN-114805487-A | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-20220096669-A1 | SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-03-31 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096669-A1 | SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF | FOLH1, KLK3, FRS2 | KMT2A 706/4885MDM2 3205/4885MDM4 3612/4885 |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | KMT2A 3970/4885MDM2 1966/4885MDM4 4771/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | KMT2A 4043/4885MDM2 1979/4885MDM4 4779/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | KMT2A 3970/4885MDM2 1966/4885MDM4 4771/4885 |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | SHBG, SLC40A1, TFRC | KMT2A 3931/4885MDM2 3583/4885MDM4 1896/4885 |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | KLK3, FOLH1, SLC7A1 | KMT2A 1100/4885MDM2 3098/4885MDM4 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.